Worldwide Clinical Trials appoints vp, Oncology Medical Affairs
Gerald Messerschmidt joins firm from Talon Therapeutics
Messerschmidt has more than 20 years’ clinical and operational leadership in the development of critical therapies for a multitude of oncology indications, the firm said. His portfolio of experience includes small molecules, biologic products, medical devices, genetic modification of living organisms and immune modulation therapy.
Prior to joining Worldwide Clinical Trials, Messerschmidt held the position of vp, Clinical Development at Talon Therapeutics (formerly Hana Biosciences) where he co-led the successful development of Marqibo, a new liposome plus vincristine product. From 2008–2010, Messerschmidt held senior positions within oncology at Onyx Pharmaceuticals and Icon Clinical Research, preceded by leading Wild-Type Enterprises as chairman and ceo from 2000–2008.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Regulatory
NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case
The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach
Regulatory
FDA grants Breakthrough Therapy designation to BeOne Medicines' sonrotoclax
The designation comes after positive early results of a Phase I/II study in patients with relapsed or refractory mantle cell lymphoma, with BeOne aiming to participate in Project Orbis programme to advance global access